All relevant data are within the paper or detailed in the references provided in the paper, or contained in the Supporting Information files. The optima HIV model visual interface can be accessed at: <http://hiv.optimamodel.com/#/login>, alternately Optima HIV sourcecode can be accessed at: <https://github.com/optimamodel/optima>.

Introduction {#sec005}
============

Substantial scale-up of HIV testing and treatment in Eswatini has led to a 44% decrease in new HIV infections; from 23.1 new infections per 1,000 adults aged 15--49 years in 2014 to 15.4 in 2018 \[[@pone.0235664.ref001], [@pone.0235664.ref002]\]. This progress together with reductions in disability and HIV-related deaths are tied to continuous increases in national and international funding of the HIV response \[[@pone.0235664.ref003]\]. Despite encouraging progress, HIV remains Eswatini's leading cause of disability and death \[[@pone.0235664.ref004]\], with one the highest rates of HIV incidence in the world \[[@pone.0235664.ref001]\].

To end the HIV epidemic in Eswatini, onwards transmission of the virus must be prevented. In line with the 2014 call from UNAIDS for increased investment in HIV prevention to 25% of total HIV budgets \[[@pone.0235664.ref005]\], the Government of Eswatini made prevention one of the four key tenants of the HIV response in their 2018--2023 extended National Strategic Framework (eNSF) \[[@pone.0235664.ref006], [@pone.0235664.ref007]\]. The country's target is to reduce new HIV infections by 85% over the five-year eNSF period. The proposed strategy to achieve this reduction is to implement high-impact core interventions including a combination of HIV prevention strategies, to scale up treatment and care services, and to strengthen cross-cutting areas to produce an enabling environment for improving gender equity and empowerment of women \[[@pone.0235664.ref007]\].

Reaching eNSF targets in Eswatini will depend on resource availability. Despite the substantial burden of HIV in Eswatini, continued increases in HIV donor funding is not expected, rather funding cuts are anticipated in the future \[[@pone.0235664.ref003]\]. Moreover, stalling national economic growth and ongoing recession caused by inadequate public financing may result in decreased government spending on HIV \[[@pone.0235664.ref008]\]. Therefore, to maximize health gains more cost-effective investment of available HIV resources is essential.

A previous allocative efficiency modelling analysis conducted in Eswatini demonstrated that substantial gains may be possible by better allocating resources across the current mix of broad HIV program categories, such as HIV testing and treatment \[[@pone.0235664.ref009]\]. Recommendations from this study were considered by the national government and Ministry of Health as part of the HIV strategic planning process. In addition to allocative efficiencies, it was noted that further gains could also be realized by improving efficiencies in service delivery. In 2016, Eswatini's national AIDS program implemented a differentiated care approach for delivery and refill of antiretroviral (ARV) drugs \[[@pone.0235664.ref010]\]. Furthermore, in 2019, the national government highlighted the need for expansion of HIV testing service modalities to better target testing resources towards increasing HIV diagnoses \[[@pone.0235664.ref011]\]. This is with the recognition that a one-size-fits-all model of HIV service delivery will not lead to the greatest success in providing sustainable and efficient service delivery. Improving implementation by optimizing funding across both broad HIV programs but also the most cost-effective and efficient prevention and care modalities may prevent more new HIV infections and HIV-related deaths with less resources, without sacrificing quality of care.

In the face of potential funding cuts, we explored approaches to improve the cost-effectiveness of HIV prevention and treatment in Eswatini through a modelling analysis in line with eNSF objectives. We focused on two areas of efficiency, allocative and implementation efficiency. To highlight potential improvements in these two areas we modelled an optimized allocation of Eswatini's most recently reported national annual HIV budget, US\$123 million in 2017, of which \$63 million was invested in programs whose direct impact on the HIV epidemic could be readily modelled. The impact of improving both areas of efficiency was determined by estimating the number of HIV infections and HIV-related deaths that could be averted and the amount of program coverage and cost savings that could be gained.

Methods {#sec006}
=======

Mathematical model {#sec007}
------------------

Optima HIV (hiv.optimamodel.com version 2.6.11), a dynamic population-based compartmental model, was applied in this study \[[@pone.0235664.ref012]\]. Optima HIV has been used to conduct national and subnational HIV investment cases and strategy development in other settings. Various examples of findings from Optima HIV studies being used to help inform evidence-based HIV strategies can be found on the aforementioned Optima website. The Optima HIV model tracks HIV transmission dynamics between population groups incorporating assumptions around interactions between populations, behavioural parameters, and transmissibility of HIV. The epidemic model is overlaid with a module incorporating the cost, coverage, and outcome of programs targeted at reducing new HIV infections, HIV-related morbidity, and HIV-related deaths, such as antiretroviral therapy (ART) and condom programs. The effect of each program on the epidemic is informed by program spending, coverage, and unit costs over time. An adaptive stochastic descent optimization algorithm is applied within the model to estimate the optimized resource allocation for a given budget level against defined constraints and objective function weights. The weighting used for this analysis was 1 to 1 for minimizing new HIV infections to HIV-related deaths. The algorithm forms probabilistic assumptions about which parameters, such as changes in spending on programs that will influence prevention, treatment, and/or other outcomes, will have the greatest effect on minimizing infections and deaths \[[@pone.0235664.ref012]\].

The total HIV budget of US\$123 million invested in 2017 in Eswatini was optimized to minimize new HIV infections and HIV-related deaths between 2018 and the end of 2022 in line with Eswatini's 2018--2023 extended National Strategic Framework (eNSF) \[[@pone.0235664.ref007]\]. For this analysis, an existing Optima HIV model for Eswatini from previous modeling exercises \[[@pone.0235664.ref009], [@pone.0235664.ref013], [@pone.0235664.ref014]\] was updated with more recent data in consultation with partners from the Eswatini Ministry of Health and the World Bank Group.

Model inputs and calibration {#sec008}
----------------------------

The model was informed using demographic, epidemiological, and behavioural data and estimates by population group, along with programmatic expenditures and coverage levels from 2000 to 2017. Values used to inform the model, as well as their data sources, are summarized in [S1](#pone.0235664.s004){ref-type="supplementary-material"}--[S6](#pone.0235664.s009){ref-type="supplementary-material"} Tables.

We initialized the model in 2000 using existing data to produce projections from 2019 to 2023. We calibrated the model to data and estimates for population size, HIV prevalence by population, numbers of people diagnosed with HIV, and those on ART for 2000 to 2017. Comparisons of goodness of fit to estimates from other models for new HIV infections, HIV-related deaths, and people living with HIV (PLHIV) were carried out. Calibration curves are shown in the [S1](#pone.0235664.s001){ref-type="supplementary-material"}--[S3](#pone.0235664.s003){ref-type="supplementary-material"} Figs. Projections were then produced from 2019 to 2023.

Cost functions {#sec009}
--------------

The cost-effectiveness of each HIV program or intervention in the model is defined by its cost function. Costs functions are defined by the relationship between spending and coverage and coverage and outcome, reflecting the number of individuals reached by the program for each dollar spent and the impact of this spending. Cost functions also model the increasing marginal cost associated with covering higher proportions of a targeted population. As costs increase, cost functions can become saturated, which reflects the point where increasing a program budget will no longer result in increased coverage, analogous to the challenges in providing services to the hardest to reach individuals within a population. Cost functions for each intervention can be found in supplementary material S2.

Allocative efficiency analysis approach {#sec010}
---------------------------------------

The model was applied to analyse the allocative efficiency of the current HIV response using the latest reported spending by HIV program. HIV programs considered within the optimization were those that have a direct and readily measurable impact on reducing HIV transmission, morbidity, and/or mortality, including prevention and treatment programs, referred to as targeted programs. Targeted HIV programs included in this study were; efforts to keep girls in school (i.e., conditional cash transfer programs targeting adolescent girls and young women aged 15 to 24 years); condom distribution programs; social and behaviour change communication (SBCC); voluntary medical male circumcision (VMMC); antiretroviral-based prophylaxis, including pre- and post-exposure prophylaxis; HIV prevention and testing programs targeting female sex workers (FSW); HIV prevention and testing programs targeting men who have sex with men (MSM); HIV testing services (HTS); linkage to care appointment support and telephone follow-up; enhanced adherence counselling; text messaging appointment reminders; text messaging adherence support; pre-ART tracing for those who miss their appointments; prevention of mother-to-child HIV transmission (PMTCT); and antiretroviral therapy (ART). Non-targeted HIV programs, such as program management and human resources, are an important part of the HIV response, but whose effect cannot be readily measured. As such non-targeted HIV programs were not considered within the optimization but handled by fixing their spending. Certain HIV program implementation costs, such as infrastructure costs, were also classified as non-targeted and not considered within the optimization. Non-targeted HIV programs for which spending data was available, but were not considered in the optimization included programs for orphans and vulnerable children (OVC) affected by HIV; infrastructure; enabling environment; human resources; management; monitoring and evaluation (M&E); social protection; other non-disaggregated HIV prevention costs; other HIV care costs; and other HIV costs. Costing data used to inform the model were from a provider perspective as the analysis was conducted primarily to inform national strategic decision making. Out-of-pocket costs incurred by people accessing HIV services were not included.

An optimization algorithm was applied to estimate the most cost-effective allocation of resources across the above combination of HIV interventions to minimize new HIV infections and HIV-related deaths from 2019 to 2023. The latest reported HIV budget for Eswatini was US\$123 million for 2017, of which US\$63 million was invested in targeted HIV programs and considered in the optimization. We also applied the algorithm to sequential increases and decreases of the most recent budget (50%, 90%, 100%, 110%, 150%, and 200%) to estimate the potential impact of varying budget on optimized allocation. HIV program spending, unit cost, and saturation values are shown in [Table 1](#pone.0235664.t001){ref-type="table"}.

10.1371/journal.pone.0235664.t001

###### HIV program spending, unit cost, and saturation.

![](pone.0235664.t001){#pone.0235664.t001g}

  HIV programs and modalities                                                                                    Spending (USD)                                       Unit cost (USD)                                  Saturation                                                     
  -------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------ ------------------------------------------------ ------ ------ ------
  HIV prevention                                                                                                                                                                                                                                                                      
   Condom programs                                                                                               \$2,893,393                                          \$4.54[^a^](#t001fn001){ref-type="table-fn"}     \$5.55[^a^](#t001fn001){ref-type="table-fn"}     2016   75%    80%
   Efforts to keep girls in school                                                                               \$61,083[^a^](#t001fn001){ref-type="table-fn"}       \$25.00[^a^](#t001fn001){ref-type="table-fn"}    \$36.00[^a^](#t001fn001){ref-type="table-fn"}    2016   40%    80%
   PEP (combined with PrEP as ARV-based prophylaxis)                                                             \$0                                                  \$18.00[^a^](#t001fn001){ref-type="table-fn"}    \$28.00[^a^](#t001fn001){ref-type="table-fn"}    2018   2%     30%
   PrEP (combined with PEP as ARV-based prophylaxis)                                                             \$78,840 \[[@pone.0235664.ref015]\]                  \$179.00 \[[@pone.0235664.ref015]\]              \$219.00 \[[@pone.0235664.ref015]\]              2018   35%    36%
   Programs targeting men who have sex with men (MSM)                                                            \$573,413[^b^](#t001fn002){ref-type="table-fn"}      \$158.85[^b^](#t001fn002){ref-type="table-fn"}   \$194.15[^b^](#t001fn002){ref-type="table-fn"}   2017   70%    80%
   Programs targeting female sex workers (FSW)                                                                   \$155,140[^b^](#t001fn002){ref-type="table-fn"}      \$100.00[^b^](#t001fn002){ref-type="table-fn"}   \$125.00[^b^](#t001fn002){ref-type="table-fn"}   2016   80%    90%
   Social and behaviour change communication (SBCC)                                                              \$4,226,272                                          \$12.91                                          \$15.78                                          2016   80%    90%
   VMMC---fixed sites/public integrated                                                                          \$979,810[^c^](#t001fn003){ref-type="table-fn"}      \$115.00[^c^](#t001fn003){ref-type="table-fn"}   \$145.00[^c^](#t001fn003){ref-type="table-fn"}   2013   40%    80%
   VMMC---other costs                                                                                            \$2,217,106[^c^](#t001fn003){ref-type="table-fn"}    \$433.00[^c^](#t001fn003){ref-type="table-fn"}   \$529.00[^c^](#t001fn003){ref-type="table-fn"}   2016   40%    80%
   VMMC---outreach                                                                                               \$3,177,533[^c^](#t001fn003){ref-type="table-fn"}    \$115.00^c^                                      \$155.00[^c^](#t001fn003){ref-type="table-fn"}   2018   40%    80%
  HIV testing                                                                                                                                                                                                                                                                         
   HIV testing---overall                                                                                         \$4,190,502                                          \$10.13                                          \$12.39                                          2017   80%    95%
   HIV testing---home-based                                                                                      \$4,598[^g^](#t001fn007){ref-type="table-fn"}        \$9.90[^g^](#t001fn007){ref-type="table-fn"}     \$12.10[^g^](#t001fn007){ref-type="table-fn"}    2017   40%    60%
   HIV testing---index                                                                                           \$14,750[^f^](#t001fn006){ref-type="table-fn"}       \$4.50[^f^](#t001fn006){ref-type="table-fn"}     \$5.50[^f^](#t001fn006){ref-type="table-fn"}     2017   10%    20%
   HIV testing---mobile                                                                                          \$1,952,610[^e^](#t001fn005){ref-type="table-fn"}    \$27.00[^e^](#t001fn005){ref-type="table-fn"}    \$33.00[^e^](#t001fn005){ref-type="table-fn"}    2017   55%    65%
   HIV testing---other provider-initiated testing and counselling (PICT)[^m^](#t001fn013){ref-type="table-fn"}   \$1,604,414                                          \$6.30                                           \$7.70                                           2016   45%    65%
   HIV testing---self-testing                                                                                    \$56,050[^h^](#t001fn008){ref-type="table-fn"}       \$22.50[^h^](#t001fn008){ref-type="table-fn"}    \$27.50[^h^](#t001fn008){ref-type="table-fn"}    2017   35%    45%
   HIV testing---voluntary counselling and testing (VCT)[^n^](#t001fn014){ref-type="table-fn"}                   \$684,504                                            \$8.10                                           \$9.90                                           2016   20%    30%
  Treatment                                                                                                                                                                                                                                                                           
   Antiretroviral therapy (ART)                                                                                  \$39,521,381[^a^](#t001fn001){ref-type="table-fn"}   \$202.37[^a^](#t001fn001){ref-type="table-fn"}   \$247.34[^a^](#t001fn001){ref-type="table-fn"}   2017   90%    99%
   Dolutegravir (DTG)-based ART                                                                                  NA                                                   \$181.00[^d^](#t001fn004){ref-type="table-fn"}   \$221.23[^d^](#t001fn004){ref-type="table-fn"}   2017   90%    99%
   Prevention of mother-to-child transmission (PMTCT)                                                            \$7,232,881[^b^](#t001fn002){ref-type="table-fn"}    \$707.40[^b^](#t001fn002){ref-type="table-fn"}   \$846.61[^b^](#t001fn002){ref-type="table-fn"}   2017   100%   100%
  ART refill modality                                                                                                                                                                                                                                                                 
   Community-based group ART                                                                                     \$212,044[^i^](#t001fn009){ref-type="table-fn"}      \$165.09[^i^](#t001fn009){ref-type="table-fn"}   \$201.77[^i^](#t001fn009){ref-type="table-fn"}   2017   20%    45%
   Facility-based group ART                                                                                      \$793,587[^j^](#t001fn010){ref-type="table-fn"}      \$169.05[^j^](#t001fn010){ref-type="table-fn"}   \$206.62[^j^](#t001fn010){ref-type="table-fn"}   2017   30%    50%
   Fast-Track ART                                                                                                \$1,137,729[^k^](#t001fn011){ref-type="table-fn"}    \$151.07[^k^](#t001fn011){ref-type="table-fn"}   \$184.64[^k^](#t001fn011){ref-type="table-fn"}   2017   50%    60%
   Mainstream ART                                                                                                \$12,520,055[^a^](#t001fn001){ref-type="table-fn"}   \$204.87[^a^](#t001fn001){ref-type="table-fn"}   \$250.40[^a^](#t001fn001){ref-type="table-fn"}   2017   100%   100%
   Outreach ART                                                                                                  \$461,235[^l^](#t001fn012){ref-type="table-fn"}      \$409.38[^l^](#t001fn012){ref-type="table-fn"}   \$500.35[^l^](#t001fn012){ref-type="table-fn"}   2017   70%    80%

^a^Calculated based on the National Operational Plan \[[@pone.0235664.ref006]\],

^b^Calculated based on data from the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) and the President's Emergency Plan for AIDS Relief (PEPFAR),

^c^Calculated based on expert opinion from PEPFAR and on the Swaziland male circumcision strategic and operational plan for HIV prevention, 2014--2018. Swaziland Government, Ministry of Health \[[@pone.0235664.ref016]\],

^d^Calculated based on the National Operational Plan \[[@pone.0235664.ref006]\] and expert opinion from UNAIDS representatives,

^e^Calculated using data from the Determined Resilient Empowered AIDS-free Mentored Safe (DREAMS) project,

^f^Calculated using data from the CommLink project managed by PEPFAR,

^g^Calculated using data from Population Services International (PSI)

^h^Calculated using data from Médecins Sans Frontières (MSF),

^i^Calculated using data from Médecins Sans Frontières (MSF) for community-based ART refill groups for Mozambique,

^j^Calculated using data from *Max*ART \[[@pone.0235664.ref017]\],

^k^Calculated using expert opinion from an Optima HIV application in Malawi,

^l^Calculated using data from Moreland et al. Monitoring and Evaluation to Assess and Use Results (MEASURE) Evaluation; 2013 \[[@pone.0235664.ref018]\],

^m^Defined as any HIV testing modality that is recommended by healthcare providers as a standard component of care,

^n^Defined as client-initiated HIV testing delivered at a free standing health facility and through community outreach.

Implementation efficiency analysis approach {#sec011}
-------------------------------------------

We used the model to estimate the potential impact of four strategies to identify potential efficacies in differentiated care and service implementation.

First, the impact of switching from mainstream ART to optimized differentiated ART care modalities for stable patients (described in [Table 2](#pone.0235664.t002){ref-type="table"}) was estimated. This included assessing costs, coverage, retention, and viral suppression for each modality. The potential for increased treatment coverage for people living with HIV and the number of infections and deaths that could be averted were also assessed. Improvements in efficiency based on optimized differentiated care was examined in two ways: \[[@pone.0235664.ref001]\] using the ART budget level from the allocative efficiency optimization and optimally redistributing this budget across the most cost-effective antiretroviral (ARV) refill options and \[[@pone.0235664.ref002]\] using the level of ART coverage from the allocative efficiency optimization achieved via mainstream ARV refill alone and optimally distributing surplus budget that could be gained through less expensive refill modalities across the most cost-effective refill options.

10.1371/journal.pone.0235664.t002

###### Description of antiretroviral (ARV) refill modalities \[[@pone.0235664.ref010]\].

![](pone.0235664.t002){#pone.0235664.t002g}

  ARV refill modalities        Overview                                                                                                                           Number of visits per year                                                         Priority implementation site                                                                                                                     Benefits
  ---------------------------- ---------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------
  Community -based group ART   Groups of 2--6 with people taking turns visiting the facility to collect refills on behalf of themselves and other group members   Variable, 2--4 clinic visits or 4--12 community group meetings                    Where there are pre-existing networks, people are in hard-to-reach areas, among families                                                         Increased peer support, decreased visits to the facility, reduced cost
  Facility-based group ART     Up to 20 people meet for group counselling and collection of ARVs                                                                  4 in total (2 ARV refill visits and group + 2 clinical consultations and group)   High-volume sites in a crowded facility, for people with constraints on availability needing early morning refill appointments, special groups   Reduced waiting time, decreased congestion, peer support
  Fast-Track ART               No consultation, direct collection of ARV refill                                                                                   4 total (2 ARV refill visits plus 2 clinical consultations)                       High-volume sites, crowded facilities, where clients have constrained working hours and need early morning refills, for special groups           Reduced waiting time, decreased congestion
  Mainstream ART               For people who require close clinical attention and/or monitoring                                                                  Variable                                                                          All ART sites                                                                                                                                    Intense clinical services available as required
  Outreach ART                 Mobile teams from facilities offer ART services in the community                                                                   1--12 depending on the number of outreach visits a facility can fund              Where people are in hard-to reach areas                                                                                                          Increased access, reduced time and cost to people living with HIV

Second, we estimated an optimized resource allocation across HIV testing modalities (described in [Table 3](#pone.0235664.t003){ref-type="table"}). The optimized allocation for the HIV testing budget to minimize new HIV infections and HIV-related deaths was determined as part of the overall optimization. The budget amount for HIV testing was then optimized across the most cost-effective HIV testing modalities, using unit cost per HIV diagnosis to represent cost-effectiveness of each testing modality. Ranges for maximum coverage (i.e., saturation) for each modality were agreed upon with national representatives.

10.1371/journal.pone.0235664.t003

###### Description of HIV testing modalities.

![](pone.0235664.t003){#pone.0235664.t003g}

  HIV testing modality                                      Overview                                                                                                                                                              Priority implementation site         Benefits
  --------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------------
  Home-based testing                                        Community-based HIV testing provided door-to-door at the homes of community members                                                                                   Rural areas                          Accessing first-time testers and rural populations
  Index testing                                             Active and systematic HIV testing of sexual partners, biological children, injecting drug users, and associates of index cases diagnosed with HIV                     Facility or community-based          Reduced cost and increased yield
  Mobile testing                                            Community-based HIV testing provided through mobile units                                                                                                             Rural areas and workplace settings   Accessing harder to reach vulnerable populations
  Other provider-initiated testing and counselling (PITC)   HIV test is routinely recommended and offered by healthcare providers to people attending healthcare facilities as a standard component of care                       All healthcare facilities            Increased HIV testing coverage among those who seek healthcare services, relatively low cost
  Self-testing                                              HIV screening test to increase awareness of HIV status resulting in benefits such as reduced risk of onward HIV transmission                                          Facility or community-based          Accessed by harder to reach populations such as key populations, adolescents, and men
  Voluntary counselling and testing (VCT)                   Individuals presenting for and initiating HIV testing via health facilities, free standing sites, or community outreach; also known as client-initiated HIV testing   All healthcare facilities            People can seek HIV testing if they believe to be a risk of having acquired HIV, relatively low cost

Third, we explored the potential costs that could be saved by switching non-pregnant adults from the standard ART to a Dolutegravir (DTG) regimen. DTG has a 25% lower drug unit cost than the standard ART and has been shown to be safe and at least as effective as other regimens in averting HIV-related disability-adjusted life years \[[@pone.0235664.ref019]\].

Finally, we estimated the impact of potential efficiencies in implementation efficiency of voluntary male medical circumcision (VMMC) service delivery. Namely potential savings that could be realized if start-up costs for mobile clinic VMMC delivery were eliminated through centralization of VMMC at existing fixed healthcare sites. Efficacy for these two VMMC modalities did not differ, only unit cost.

Results {#sec012}
=======

Potential impact of an optimized budget {#sec013}
---------------------------------------

In Eswatini, 85% of those diagnosed with HIV received ART in 2016--2017 \[[@pone.0235664.ref002]\]. Based on our optimization of the most recent budget and towards increasing treatment coverage to prevent deaths and infections through treatment as prevention, it is first recommended to increase investment in HIV testing from 3% of the total budget reported for 2017 to 6% for 2018 to the end of 2022 ([Fig 1](#pone.0235664.g001){ref-type="fig"}). This will allow more people to be diagnosed with HIV so they can modify their risk behaviour, prevent onwards HIV transmission, receive treatment, and achieve viral suppression. Eswatini has a generalized HIV epidemic, but there is also ongoing transmission from commercial sex in the country. As such, findings from our analysis suggest that HIV testing and prevention programs targeting female sex workers should be prioritized. In addition, it is also recommended to prioritise efforts to keep girls in school, condom distribution, VMMC, and ARV-based prophylaxis including pre- and post-exposure prophylaxis. It is estimated that if the US\$123 million HIV budget for Eswatini reported for 2017 is optimally reinvested from 2018 to the end of 2022, approximately 1,000 more new HIV infections (2% more) and 100 more HIV-related deaths (1% more) could be averted over this period ([Fig 2](#pone.0235664.g002){ref-type="fig"}). This would represent an overall reduction in new HIV-infections of 45% and 48% in HIV-related deaths from in 2022 compared with 2017 levels, falling short of the eNSF goals of 85% and 50%, respectively.

![Optimized allocations for varying HIV budget levels compared with baseline.](pone.0235664.g001){#pone.0235664.g001}

![Estimated new HIV infections under optimized allocations for varying HIV budget levels.](pone.0235664.g002){#pone.0235664.g002}

Optimization of varying budget levels {#sec014}
-------------------------------------

If Eswatini's HIV budget were to be reduced by 50%, even if optimally allocated, we estimate that there could be over 170% more new infections and 40% more HIV-related deaths from 2018 to the end of 2022 compared with baseline ([Fig 2](#pone.0235664.g002){ref-type="fig"}). At half the budget level under optimized allocation all programs other than treatment (including ART and PMTCT) are deprioritized. If the budget were cut by only 10% (to 90% of the latest reported amount) and optimally allocated, 1% more new HIV infections and almost 1% more HIV-related deaths could still be averted by the end of 2022 compared with maintaining the latest reported budget allocation and level.

It was estimated that if the budget level were to be increased to 110%, 150%, or 200% and optimized, an additional 7%, 15%, or 18% of new HIV infections could be averted by the end of 2022, respectively. This indicates marginal decreasing returns on investment with increasing budget somewhere above 150%. If the budget were to be increased to 110% and allocation optimized, it is recommended to prioritize HIV testing, condom programs, efforts to keep girls in school, and adherence programs. At higher optimized budget levels of 150% and 200%, after the maximum number of people are tested in a given year, further infections could be averted by prioritizing prevention programs that target the general population such as VMMC, prevention of mother-to-child transmission (PMTCT), programs to keep girls in school, ARV-based prophylaxis, social and behaviour change communication (SBCC), and to a lesser extent condom programs.

Optimizing HIV testing and ART budgets across delivery modalities {#sec015}
-----------------------------------------------------------------

Based on the allocative efficiency analysis, it is recommended to increase investment in HIV testing from the latest reported US\$4.2 million (3% of the total HIV budget) to US\$7.3 million (6% total budget) ([Fig 1](#pone.0235664.g001){ref-type="fig"}). We estimated that if this US\$7.3 million optimized allocation was redistributed across the most cost-effective mix of HIV testing modalities, including redistributed towards index and self-testing, an additional 100,000 people could be tested by 2023, including those who are less likely to receive facility based testing ([Fig 3](#pone.0235664.g003){ref-type="fig"}).

![Estimated HIV testing coverage under optimized allocation across testing modalities.](pone.0235664.g003){#pone.0235664.g003}

We estimate that if 50% to 60% of non-pregnant adults on ART with stable viral suppression were shifted from the mainstream refill option to Fast-Track, community- and facility-based groups for their ARV refills, an additional 30,000 people could receive treatment by 2023 with the same amount of funding ([Fig 4](#pone.0235664.g004){ref-type="fig"}). Alternatively, if ART coverage was maintained over this period but the ART budget optimized across the most cost-effective ARV refill options, US\$5.5 million in cost savings could be realized, effectively reducing the annual treatment unit cost from US\$227 to US\$192. These savings could then be optimally allocated following the allocations for increased budget shown in [Fig 1](#pone.0235664.g001){ref-type="fig"}.

![Estimated budget allocation and coverage for optimization across differentiated ART care modalities.](pone.0235664.g004){#pone.0235664.g004}

We estimate that if all non-pregnant adults living with HIV were switched to a DTG-based antiretroviral regimen, \$4.5 million in savings available for optimal re-investment (4% of the total HIV budget) could be realized by the end of 2022. We also estimate that by performing voluntary male medical circumcisions at existing fixed sites rather than at mobile outreach units, effectively removing start-up costs surrounding mobile units, either an annual savings of US\$6.6 million could be achieved and reinvested or an additional 26,500 males could be medically circumcised each year in Eswatini. This approach to improve implementation efficiency of VMMC could effectively result in an average program unit cost of US\$140 (validated by country experts for planning purposes) compared with the latest derived unit cost of US\$364 (estimated from top-down costing using data obtained from implementing partners for baseline coverage and expenditure including start-up costs).

Discussion {#sec016}
==========

Findings from this modelling study highlight the potential for greater efficiency in the HIV response in Eswatini through optimization of budget allocation and service delivery. Based on our analysis, we recommend scaling up HIV testing targeting the general population to diagnose more people who can then receive treatment. This will reduce onwards transmission of HIV; however, these results suggest a relatively modest number of infections and deaths could be averted. Recommendations provided from this analysis align with those from a previous optimization analysis conducted in Eswatini \[[@pone.0235664.ref009]\]. Previously it was also recommended to prioritize ART, VMMC, and HIV testing \[[@pone.0235664.ref009]\], which was adopted by the Government of Eswatini and the National AIDS Program. As such a large proportion of the latest reported HIV budget had already been cost-effectively committed to treatment (60% of the targeted budget), leading to 85% of those diagnosed with HIV receiving ART in 2017 \[[@pone.0235664.ref001]\]. With an already mainly optimized budget allocation, if recommendations from this optimization analysis were to be adopted, an additional 2% infections and 1% deaths could be averted from 2018 to the end of 2022.

Since the five-year 2018--2023 eNSF timeframe is relatively short, even under modelled optimized resource allocation it is predicted that Eswatini is unlikely to reach the eNSF prevention target of reducing new HIV infections by 85% by the end of 2022 over 2017 levels. Notably, it is not anticipated that the target would be met even if the total HIV budget were doubled and optimally allocated. The inability to reach eNSF targets even with relatively large increases in budget demonstrates the marginally decreasing return on investment in the HIV response over a short timeframe. It also highlights the effect of the inability to provide services to harder to reach populations. Achieving national prevention targets will require identifying additional cost-effective implementation efficiencies, since reaching those living with HIV who are hardest to reach will be increasingly more expensive \[[@pone.0235664.ref020]\]. Regardless, remarkable progress has been made by the country to reduce its incidence of HIV and HIV-related mortality. Progress could however be accelerated over the eNSF time period even with the same budget level, as demonstrated by these modeling results. If HIV funding were to be reduced as is anticipated with donor funding being withdrawn, HIV incidence can still be lessened by finding allocative and implementation efficiencies. Regardless of changes in overall budget, our analysis suggests that efficiency gains can be realized through optimizing HIV budget allocation in Eswatini, which in turn may allow increased productivity and may improve progress on human capital \[[@pone.0235664.ref021]\].

Our model approximates real-world constraints. These include limits on maximum attainable coverage which mimic the difficulty of rapid scale up of HIV programs. It also incorporates the increasing marginal cost associated with covering high proportions of the population. This impacts program cost-effectiveness and suggests that once a program has reached its theoretical saturation point, increased funding may be better invested in programs previously less prioritized, yet still relatively cost-effective, such as VMMC and PMTCT. Our optimized varying budget analysis demonstrates that at higher optimized budget levels (i.e., 150% and 200%), spending on ART and HIV testing make up decreasing proportions of the overall increased budget. This is due to greater estimated impact through scale-up of prevention activities to minimize HIV transmission among women, including programs which help keep girls in-school, ARV-based prophylaxis, and HIV testing and prevention programs targeting female sex workers. This aligns with HIV epidemic trends in Eswatini where the largest proportion of HIV transmission occurs among females aged 25 to 49 years, female sex workers, and girls aged 15 to 24 years who are not attending school \[[@pone.0235664.ref011]\].

Should there be less funding for HIV, progress made towards Eswatini's targets could be reversed. Decreases in budget, however, remain a real possibility as donor investment in HIV has declined and is expected to continue to decline in the future \[[@pone.0235664.ref022]\]. With no increase in funding or reduced funding expected, now more than ever efficiencies must be leveraged and available resources optimally invested. Our findings show that implementation efficiencies can be actualized by optimizing across cost-effective modalities. For example, in Eswatini strategies for refilling ARV prescriptions may benefit from switching non-pregnant adults with stable viral suppression to less costly Fast-Track, facility- and community-based group refill options. This may in turn reduce congestion in standard refill streams and allow even more people to be sustained on treatment \[[@pone.0235664.ref010]\]. Community-based ART groups reduce stress on the healthcare system by allowing multiple patients to share the logistic burden of collecting their drug refills. Outreach ART allows services to be expanded and targeted towards hard-to-reach populations, and may also have additional benefits not modelled here, such as reduced out- of-pocket costs associated with collecting ARVs \[[@pone.0235664.ref010]\]. These recommendations, however, should be balanced with context-specific considerations not evaluated in this modelling study, such as equity of access and differences in cost associated with delivering ART in urban versus rural settings.

Efficiencies in delivering HIV testing services may be found by prioritizing index testing, which may result in higher yields. This approach increases the likelihood of diagnosing someone living with HIV by targeting close contacts of those already diagnosed \[[@pone.0235664.ref023]\]. Prioritizing HIV self-testing may also lead to increased yield as hard-to-reach populations may be more accepting of this private and more accessible method. Switching non-pregnant adults on stable treatment to lower cost ARV drugs, such as DTG-based regimens, may result in cost savings. Finally, savings may be found through integration of service delivery and other approaches for health system strengthening by leveraging pre-existing infrastructure, such as delivering VMMC at fixed sites \[[@pone.0235664.ref024]\]. Prioritizing public fixed or integrated VMMC sites over mobile sites is likely to be more cost-effective, as it would bring about lower unit costs.

As with any modelling study, results from this analysis are estimates and should be interpreted accordingly. Our analysis is also subject to the following limitations. First, limitations in data availability and reliability can lead to uncertainty about projected results. Contextual values and expert opinion were used where available to inform the model, and otherwise evidence from systematic reviews of clinical and research studies were sourced. Although the model optimization algorithm accounts for inherent uncertainty, it might not be possible to account for all aspects of uncertainty because of poor quality or insufficient data, particularly for important cost values. Coupled with epidemic burden, cost functions are a primary factor in modelling optimized resource allocations. It is important to note that there is currently no expenditure tracking system in Eswatini and the last completed National AIDS Spending Assessment (NASA) was only available for the fiscal year 2012--2013 \[[@pone.0235664.ref025]\]. Therefore, expenditures were triangulated from different sources, applying top-down costing approaches, and are informed by expert opinion in some instances. Uncertainty bounds around estimates for new HIV-infections and HIV-related deaths are available in the supplementary information ([S3 Fig](#pone.0235664.s003){ref-type="supplementary-material"}). Second, we have only included costs from a provider perspective. However, as explored in this analysis we expect that ART differentiated service delivery modalities for switching people with stable viral suppression would likely result in reduced direct and indirect costs to people on care through a reduced number of clinic visits compared with mainstream ARV refill. These potential extra savings were not captured. Third, while we acknowledge the impact of migration on the HIV epidemic in Eswatini, we did not model the potential effect migration of people living with HIV coming from countries other than Eswatini, nor the dynamics of seasonal migration. Fourth, as Optima HIV is a population-based compartmental model, the full heterogeneity for HIV acquisition risk and testing and treatment seeking behaviour may not be captured. Finally, these findings are only modelling analysis projections and have not been confirmed in a practical setting in Eswatini.

Conclusions {#sec017}
===========

Exploration of areas of efficiency within Eswatini's HIV response is crucial to further increase coverage of preventive services and reduce incidence. At latest reported budget levels, prioritizing HIV testing to diagnose more people living with HIV and to increase ART initiation is the priority for limiting onwards transmission. If additional funding can be secured, either through expanding the existing HIV budget, which is unlikely, or more likely from finding efficiency in the implementation of existing programs, optimally investing in cost-effective prevention programs will help to further reduce new infections and HIV-related deaths in the country. Finding cost-savings without sacrificing coverage or improving effectiveness of service delivery at reduced cost may be important in the face of potential austerity in HIV financing. Implementation efficiency gains across program modalities, including those for VMMC, HIV testing, and differentiated treatment care may promote an increasingly strong response to HIV into the future.
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General comments:

The writing of the manuscript could be improved. There are sentences that are not very well structured throughout the manuscript.

I think the manuscript would be strengthened if it does not focus on opportunities alone but also includes the challenges. The title could be "Opportunities and challenges for improved HIV prevention and treatment through budget optimization in Eswatini".

The title does not mention "treatment", but the manuscript does include optimization of different ART care modalities. I would therefore suggest to add "treatment" to the title. See suggested title above.

In order to evaluate the validity of the study, I would like a bit more information about the Optima model and optimization functions used in the manuscript.

I am confused about the Table 1 and 2 strategies. Would it not make more sense to find the most optimal strategy among the HIV testing modalities and ART care modalities first in separate (competing choice) analyses and put the most cost-effective option in your optimization list of strategies instead of finding/optimizing the budget for e.g., treatment and then reallocating funds to the more cost-effective strategies within HIV testing modalities and ART care modalities? Currently I am not sure how you have calculated costs and effect for e.g. treatment if you do not know which ART care modality has been used (because you find the most cost-effective options after treatment budget determination).

More specific comments:

\- 1st sentence Introductions: please indicate the number of new infections per year. For example: "Since 2014, substantial scale-up of HIV testing and treatment in Eswatini has led to a 44% decrease in new infections from xxxx/1000 adults to xxxx/1000 adults annually.

\- The last sentence of the 1st paragraph of the Introduction section should be rephrased, because the sentence is not correct as it is.

\- 2nd sentence 2nd paragraph of the Introduction: I would mention that it concerns the HIV budget by rephrasing the sentence to "In line with ..... 25% of the total HIV budget on prevention, the Eswatini government .......".

\- I would clarify that the NSF period is 5 years in the last sentence of the 2nd paragraph of the Introduction: "The proposed target was a 85% reduction in new infections by the end of the 5-year NSF period (2018-2023)."

\- Can the authors add to the manuscript how the current NSF is aiming/ proposes to accomplish a 85% reduction in new HIV infections.

\- I would be interested in what the current HIV budget is in Eswatini. Can the authors mention that in the Introduction?

\- The authors mention that allocative efficiency modeling has taken place already, but it was unclear if this type of analysis was integrated in the 2018-2023 NSF. Can the authors make this more explicit in the text?

\- It was unclear whether the analysis of the current study serves to inform a strategic document. The NSF has already been published and only ends in 2023. Can the authors clarify this? It seems like a redundant analysis if the NSF 2018-2023 has already been informed by an allocative efficiency analysis. In other words, please make clear how this analysis fits in/ add to the analysis already conducted and for which strategic document (if any) this analysis has been done.

\- The authors state "Recommendations from these studies have been adopted by the country Government, and the current response may already be highly allocatively efficient." This statement is rather vague. Do we not know? I would be interested in the degree to which Eswatini has implemented the results of this allocative efficiency analysis that has been undertaken. Can the authors mention anything about that in the text?

Methods section

\- What is the budget that the authors are working with in their optimization analysis?

\- Can the authors elaborate a bit more (in a couple of sentences) on the Optima HIV model for the readers who do not know the model. The information currently provided is very scarce. I am not sure what the authors mean with a compartmental model. Also, it would be good to mention that the Optima model is a commonly-used model in costing and optimization exercises for strategic documents with some references of analyses in which the Optima model has been used.

\- Can the authors be more elaborate in the data sources section. The paragraph before that states that a prior model analysis has been updated. In the data sources section, I would be interested in what data has been updated and how for the new model.

\- In the model calibration section, it was stated that estimates were calibrated to estimates from other models, but no references were provided here. To what other models were the estimates calibrated to?

\- In the analysis approach section: how were cost functions updated? And from what? From the optimization algorithm described elsewhere? Can you add a couple of sentences describing the methodology behind the algorithm? Its hard to evaluate the validity of a study when the most crucial elements such as the optimization algorithm is not described in the current manuscript.

\- In the "impact of optimized allocative efficiency" section, please mention what the currently available budget is.

\- Is is unclear whether implementation costs are also considered in the program costs.

\- The two strategies mentioned just before the Results section (a regimen of DTG for non-pregnant adults and VMMCs) came as a surprise. If these are considered strategies in the optimization exercise these should be mentioned in the table of available treatment and prevention strategies. Now it comes across as just trying out some things.

Results section

\- It is unclear whether the strategies listed at the end of the 1st paragraph of the results section are just included in the optimization exercise or actually the chosen programs to fund based on the budget. A clarification would help. As well as a table with all strategies/programs considered for funding.

\- 2nd paragraph of the results section: please specify "a large increase in infections and deaths" by mentioning the actual number of infections and number of deaths for the budget cut of 50% or the % of increase for these 2 outcomes.

\- The results section mentions: "At higher optimised budget levels of 150% and 200%, after the maximum number of people are tested in a given year, further infections may be averted by prioritizing primary prevention programs that target the general population such as VMMC, prevention of mother-to-child transmission (PMTCT), programs to keep girls in school, ARV-based prophylaxis, social and behaviour change communication (SBCC), and to a lesser extent condom programs."

What do you mean with "may"? Are you guessing or are these the programs that should be funded based on the optimization exercise?

\- Page 10, last paragraph: do you mean 2023 instead of 2022?

\- The Results section states: "Due to a lower unit cost, public fixed or integrated VMMC sites (over mobile VMMC sites) are likely more efficient." If this is not a result of the analysis, mention it in the Discussion section instead.

\- The 2 unit costs mentioned in the last paragraph either need to be accompanied by a source reference or an explanation of how the unit cost was estimated and what exact components it consists of.

Discussion section

\- 1st paragraph: "HIV testing amongst the general population should be scaled up to diagnose more people ....". How much more? How much scale up? Be more precise here. What type of testing you are talking about (from Table 1)?

\- Have you taken into account that Eswatini has started implementing prior optimization results already? If so, how?

\- I am confused (2nd paragraph): are we not talking about the 2018-2023 NSF timeframe mentioned earlier?

\- They won't make the projected 85% reduction. Mention what they make instead in the 2nd paragraph.

\- "Exploring the possibility for switching non-pregnant adults on stable treatment to lower cost ARV drugs, such as Dolutegravir-based regimens, may result in cost savings". What do you mean with "may"? You have investigated that in this study and should now know the answer.

\- "Although the model optimisation algorithm accounts for inherent uncertainty, it might not be possible to account for all aspects of uncertainty because of poor quality or insufficient data, particularly for important cost values." What do the authors mean with inherent uncertainty? I am missing sensitivity analyses for the most important cost values. This seems important as the quality of the cost data used is difficult to evaluate.

\- In the conclusion section I would not mention the "If additional funding can be secured ..." as that is an unrealistic scenario in the light of budget cuts. I would focus on the scenario of budget reduction and the optimal spending of the current budget.

Reviewer \#2: Reviewer:

Overall, I think this is an interesting and important topic. It addressed an urgent issue in the HIV prevention in Eswatini. The findings could be used to inform and improve the current HIV practice. I have some specific suggestions below. Some expert opinions are needed for the modeling. I assumed that the modeling part was conducted properly for analyzing the questions in this paper.

Major points:

1\. For Table 1, please provide what was the targeted population in each priority implementation site. For Table 1 and Table 2, please provide what the current percent coverage was for each HIV testing modality and each ART modality in the overall population.

2\. On page 8, "measured the effect that switching eligible people to those modalities had on cost, coverage, retention, and viral suppression". Were the implementation/switching costs considered or included in the analyses besides the program costs? Please explain this point in the paper.

3\. On page 10, "A budget incorporating VMMC with reduced start-up costs and other implementation efficiencies results in an average unit cost of \$140 (estimated unit cost cited by the country for planning purposes and other bottom-up costing analyses) compared to \$364 at baseline (estimated using a top-down costing approach using data for baseline coverage and expenditure including start-up costs obtained from implementing partners)."

Are the unit costs of two scenarios comparable by using two different methods? Please justify this.

4\. In the discussion session (page 12), "Our findings show that implementation efficiencies can be actualized by optimising across cost-effective modalities."

What is the feasibility consideration regarding increasing/decreasing funding for different testing and ART modalities? How will the changes impact different groups of population, such as rural population vs. urban population, etc.? Please provider some discussion on this.

5\. In the discussion session (page 12), "Community-based ART groups reduce stress on both the healthcare system and on people needing treatment refills by allowing multiple patients to share the logistic burden of collecting their drug refills."

How would this change impact adherence? Are there studies providing evidence on this?

6\. Authors mentioned several limitations in the discussion session. One of them is that "Although the model optimisation algorithm accounts for inherent uncertainty, it might not be possible to account for all aspects of uncertainty because of poor quality or insufficient data, particularly for important cost values."

To what extent, the findings would still hold under this limitation. Have you done sensitivity analysis to explore some of those data uncertainties?

7\. In the discussion, authors mentioned the study was from a provider perspective. Please mention this in the method section and justify or explain the reasons for pick this perspective.

8\. For figure 2, except scenario "Optimized 50%", other scenarios had similar trends and results regarding the outcome, new HIV infections. It would be helpful to inform how new HIV infections change in scenarios when Optimized between 50% and 90%. This would help to show what the critical points/cutoffs are for the trends and results to change.

Minor points:

9\. On page 9, "If the budget were cut by 10% (to 90% of the latest reported amount), but with optimised allocation, an estimated 300 more new HIV infections (1% more) and 100 more HIV-related deaths (less than 1% more) could be averted by 2023. Optimised allocation of budgets increased to 110%, 150% and 200% are estimated to result in 7%, 15% and 18% fewer total new infections by 2023, respectively, showing that return on investment marginally decreases with increasing budget at these levels. With an increase to 110% optimised budget, HIV testing should be prioritized."

In the first sentence, both the number of cases and the percent increase were mentioned for both HIV-related deaths and new HIV infections. In the second sentence, only the percent decrease in new infections were mentioned. Please be consistent and add in number of cases increased/decreased for both outcomes in the second sentence.

10\. For figure 3, besides the number of people in the y-axis, please also provide the coverage in percent of total population.

11\. Please be clear about what saturation means in the supporting information. It is not completely clear to the general audience for this journal.
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